Oncodesign Services to acquire ZoBio.

Oncodesign Services, a company specializing in drug discovery and preclinical research, completed the acquisition of ZoBio, a CRO focused on small molecule drug discovery. Financial terms were not disclosed. "We are all very excited to welcome ZoBio to the Group, and thus strengthen our offering in small molecule drug discovery preclinical services from Gene-to-IND with leading-edge skills and technologies," Dr. Fabrice Viviani, Oncodesign Service, CEO.